11/27/2014

Aachen, Germany, November 27, 2014. Grünenthal announced the termination of the license agreement with Actavis for the development and commercialization of Cebranopadol, a novel analgesic for the treatment of chronic pain.

11/18/2014

Brussels, 18th November 2014. Better education on pain management and the need to foster European best practice sharing was discussed at the 5th Symposium on the Societal Impact of Pain (SIP), an international multi stakeholder platform aimed at raising awareness for the impact that pain has on our societies, health and economic systems. Pain therapy and palliative care were listed as a priority by the Italian Presidency of the EU Council and, for the first time ever, all EU ministers of health discussed this topic at the recent informal Health Council meeting in September.

10/20/2014

Aachen, Germany, October 20th 2014 Sascha Becker will be appointed to the Executive Board of the pharmaceutical company Grünenthal and take over the finance unit as Group Chief Financial Officer in the first quarter of 2015. Since 2003, Sascha Becker (43) has been working for Merck and is currently CFO of the biopharmaceutical division Merck Serono with an annual turnover of 6.3 billion Euros and 10.000 employees. He is succeeding Stefan Genten, who decided to look for new challenges outside of Grünenthal and thus did not prolong his contract that will terminate at the end of 2014.

10/2/2014

Brussels, October 2th, 2014 – The “My pain feels like…” initiative is presented today at an EU conference hosted by the European Economic and Social Committee under the patronage of the Italian Presidency in Brussels. Active Citizenship Network organized the conference to put forward European good practices in chronic pain management, and “My pain feels like…” has been chosen one of these best practices across Europe.

9/23/2014

Aachen/Brussels, September 23^rd 2014. Young scientists from any European member country of the European Pain Federation EFIC^® are invited to apply for the EFIC-Grünenthal Grant (E-G-G) 2014. This grant is one of the most prestigious and highly regarded pain research grants worldwide.

7/7/2014

Redwood City, California and Aachen, Germany – July 7, 2014 - AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grünenthal Group announced today that Grünenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO™ for the management of moderate to severe acute pain in adult patients in a medically supervised environment. ZALVISO is a drug-device combination product utilizing the opioid agonist sufentanil formulated in a proprietary sublingual tablet formulation and delivered through a pre-programmed, non-invasive proprietary delivery device.

6/17/2014

Aachen (Germany) / San Diego, CA (USA), June 17th, 2014. Grünenthal Group announces its new search fields for licensing and acquisition in R&D and for marketed assets at the 2014 BIO International Convention, the world’s largest partnering event for the biotechnology industry. The family owned, mid-sized research driven pharmaceutical company headquartered in Aachen, Germany, will be sharing with the biotech community its new approach to M&A and licensing.

5/7/2014

Aachen, May 7th 2014 – Grünenthal Group today announced the signing of an exclusive promotion and distribution agreement with MSD covering etoricoxib. This agreement covers Germany, UK, France, Belgium, Luxemburg, Ireland, and Austria. Etoricoxib is a patent-protected, selective COX-2 inhibitor, marketed under the brand name Arcoxia® in these markets.

4/8/2014

Aachen/Brussels, April 8, 2014. On the occasion of an exhibition and cocktail reception hosted by Petru Luhan, Member of the European Parliament and winner of the MEP award for Health 2013, a multi-stakeholder platform of civic organizations, patient organizations, academia and industry, call on EU institutions and national authorities to recognize the societal and individual burden of chronic pain. During the exhibition in the European Parliament, the Pain Patient Pathway Recommendations will be presented to policy makers for the first time.